Elimination of oral corticosteroids (OCS) with benralizumab treatment in OCS-dependent asthmatics using a rapid, personalized algorithm: the PONENTE trial

Abstract:

Methods This single-arm study of 598 patients assessed the efficacy and safety of daily OCS dosage reduction after initiation of benralizumab 30 mg. Adults with asthma requiring high-dosage ICS and LABA for≥ 6 months plus OCS (≥ 5 mg prednisone or equivalent) for≥ 3 months and blood eosinophil counts≥ 150/μL at baseline or≥ 300/μL in the previous 12 months were enrolled. Four weeks after benralizumab initiation, patients began an OCS dosage-reduction algorithm with rapid down-titration, including personalized reductions if AI was present. Results Most patients (62.2%[95% CI 58.18-66.11]) eliminated OCS use, and 80.6%(95% CI 77.20-83.70) eliminated use or reduced the daily dosage to≤ 5 mg if AI prevented further reduction. Median OCS daily dosage was reduced by 100%, and 91.3% of patients achieved a daily OCS dosage≤ 5 mg. OCS reductions were achieved irrespective of baseline …

Año de publicación:

2021

Keywords:

Fuente:

google